MedPath

Effect of Gamma-oryzanol in patients with high cholesterol levels

Phase 4
Conditions
Health Condition 1: E780- Pure hypercholesterolemia
Registration Number
CTRI/2020/06/026008
Lead Sponsor
AP Organics
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i.Age between 25 and 60 years

ii.Either gender & Attending diabetic clinical at hospital.

iii.Fasting serum LDL-Cholesterol > 130 mg/dl.

Exclusion Criteria

i.History of intake of dietary supplements or drugs (Retinoids, Cyclosporine, Phenothiazines) which can increase Plasma lipid level.

ii.Evidence of renal disease (S. Creatinine > 1.5mg/ml)

iii.Evidence of liver disease (AST/ALT >3 times of normal)

iv.Pregnant and lactating mothers and women intending pregnancy

v.History of alcohol intake and smoking.

vi.Participation in any other clinical trial with in the last 30 days

vii.History of intolerance or hypersensitivity Gamma-oryzanol.

viii.Any condition which in the opinion of the PI that is significant and can make the patient unsuitable for study or can place it under additional risk, such as intolerance, allergy to Gamma-oryzanol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Absolute changes in the fasting serum LDL-C level between the gamma-oryzanol and placebo groups from baseline to 12 weeksTimepoint: i. Baseline (0 week) <br/ ><br>ii. 12 weeks
Secondary Outcome Measures
NameTimeMethod
<br/ ><br>Changes in the Body Mass Index (BMI) at baseline and 12 weeksTimepoint: i. Baseline (0 week) <br/ ><br>ii. 12 weeks;Changes in Total Fat Content from baseline to 12 weeks in both the groups.Timepoint: i. Baseline (0 week) <br/ ><br>ii. 12 weeks;Mean percent changes in the Total Cholesterol, Triglycerides, VLDL-C, HDL-C levels and in the LDL/HDL ratio from baseline to 12 weeks in both the groups.Timepoint: i. Baseline (0-week) <br/ ><br>ii. 12 week;To assess the adverse drug reactions in both groupsTimepoint: Throughout the study
© Copyright 2025. All Rights Reserved by MedPath